# Final Review

**Purpose:** Log the paper's final state after all revisions
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-24T10:39:38.629845
**Response ID:** resp_030a40d90c3eba9200697492d3ab4c819c97df114aa05732c1
**Tokens:** 8208 in / 5039 out
**Response SHA256:** 7e1e659d24ceed22

---

## Referee Report (Top General-Interest Economics Journal Standard)

### Summary
The paper studies whether state authorization of dental therapists affects adult dental visit rates, using BRFSS/NOHSS state-level outcomes (biennial 2012–2020) and staggered DiD with Callaway–Sant’Anna (CS) estimators. The headline result is an ATT of about **−1.3 pp** (SE 0.6 pp; p=0.041), interpreted cautiously as possibly reflecting endogenous adoption (“reverse causation”) rather than a true causal harm.

The topic is policy-relevant and the author uses a modern staggered-adoption estimator rather than TWFE. However, at **AER/QJE/JPE/ReStud/Ecta/AEJ-Policy** standards, the current draft is not close: the empirical design does not convincingly identify the causal effect of *authorization* (as distinct from implementation), the time-series support is extremely thin (5 periods, only one usable pre-trend coefficient in the event study), and the paper reads like a short working-paper memo rather than a fully developed journal article (length, literature, robustness, mechanisms).

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norms.** The draft appears to be **~18 pages total** including references and appendices (page numbers shown through p. 18). Excluding references/appendix it is closer to **~15–16 pages**. Top general-interest journals generally expect **25–45+ pages** for an empirical policy evaluation with full robustness, institutional detail, heterogeneity, and mechanisms.

### References
- **Not adequate.** The reference list (p. 16) is short and omits a substantial body of (i) modern DiD inference/event-study diagnostics, (ii) staggered-adoption alternatives, (iii) dental workforce/dental access policy literature, and (iv) papers on Medicaid dental expansions and demand-side barriers that confound interpretation.

### Prose vs bullets
- Mostly paragraph-form in Introduction/Methods/Discussion, but:
  - Background includes bullet lists (scope of practice; p. 4–5). Bullets are fine for scope definitions, but the paper also uses bullets to carry substantive narrative in places. For a top journal, those sections should be converted into **full prose** with citations and a clearer institutional narrative (especially adoption/implementation).

### Section depth (3+ substantive paragraphs each)
- **Introduction (p. 2–3):** roughly meets.
- **Background (p. 4–5):** short; does not reach 3+ substantive paragraphs per subsection with sufficient institutional depth, especially on *implementation* differences across states.
- **Data/Empirics (p. 6–9):** adequate but thin.
- **Results (p. 10–12):** too short for top journal; should include multiple complementary outcomes, heterogeneity, and robustness.
- **Discussion (p. 13–14):** largely interpretive, but lacks disciplined tests to distinguish mechanisms.

### Figures
- Figures 1 and 2 (p. 10–12; shown in images) have axes and readable labels; Figure 2 is interpretable.
- **Figure 3 (Appendix; p. 17)** is **not publication quality** in the provided rendering: small multiples are hard to read; axis labels and treatment markers are difficult to parse. For a top journal, this must be redesigned (larger panels, consistent scales, clearer treatment timing, and uncertainty if possible).

### Tables
- Tables 1–3 contain real numbers (good).
- But there is **no regression-style table** reporting group-time ATTs, event-study coefficients with SEs, weighting, and sample composition by cohort-time cell. A top journal would expect this transparency.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors for every coefficient
- **Partially passes but not at top-journal standard.**
  - Table 3 reports ATT with **SE and p-value** (p. 12–13).
  - However, the paper does **not** report a full table of **event-study coefficients with SEs** (Figure 2 shows CIs visually, but a table is needed).
  - There is no reporting of the underlying **ATT(g,t)** estimates (the CS estimator’s core objects), nor SEs for them.

### (b) Significance testing
- Present for the headline ATT and pre-trends test (p. 11–12).
- Still incomplete: the paper should report p-values (or q-values) for the full event-study path and any multiple-testing adjustments if emphasizing specific horizons.

### (c) Confidence intervals
- Table 3 includes 95% CIs (good).
- Event study shows 95% CI shading (good), but again needs a table.

### (d) Sample sizes
- N is reported for the aggregated analysis sample (N=245 state-years; p. 6–7 and Table 3 notes).
- Missing: effective sample sizes by cohort/event time (how many states contribute to each event-time coefficient), which matters enormously with only 9 treated states.

### (e) DiD with staggered adoption
- **Passes a key minimum bar:** the author uses **Callaway & Sant’Anna (2021)** and avoids naïve TWFE (p. 8–9). This is a methodological strength.

### Inference concerns that remain “fatal” for a top journal without major work
Even though CS is used, inference is not yet convincing because:
1. **Very small treated-state count (9)** and only **5 time periods** → asymptotics are shaky; clustered SEs with 49 clusters may be borderline, but the treated-cluster count is what drives identifying variation.
2. The event-study has essentially **one pre-treatment coefficient (t=-4)** (p. 11–12), so “pre-trends tests do not reject” is weak evidence, not strong support.
3. The 2020 outcome is contaminated by COVID-era disruptions to dental utilization; this is a major confound in exactly the last period, and multiple treated cohorts load on that period.

**Bottom line:** The methodology is not “unpublishable” in the narrow sense (you do report SEs/p-values/CIs and use CS), but the *inferential credibility* is far below top-journal expectations given the thin panel and confounds. This requires a substantial redesign/augmentation.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
- The identifying assumption is **parallel trends absent treatment** (p. 8–9). The evidence offered is:
  - Figure 1 mean trends (p. 10)
  - A single pre-coefficient at event time −4 and a joint test with **df=1** (p=0.12; p. 11–12)

This is **not persuasive** at top-journal standards because:
1. **Authorization ≠ implementation.** The treatment is legislative authorization, but actual therapist entry depends on rulemaking, licensing, training programs, payer rules, dentist adoption, supervision requirements, and Medicaid billing. Without measuring implementation intensity (e.g., therapists per capita; claims; site adoption), the DiD estimates are not interpretable as effects of dental therapy availability.
2. **Endogenous adoption is likely first-order.** The paper itself highlights reverse causation (p. 13–14). That is not a “possible interpretation”; it is a serious threat that is not resolved. A top journal would require either:
   - a design that isolates plausibly exogenous timing (hard here), or
   - an explicit model/test of adoption endogeneity, or
   - complementary evidence (implementation measures, mechanisms, heterogeneous effects in targeted groups/areas) that makes the causal story credible.
3. **Concurrent shocks/policies are not addressed.** Dental utilization is affected by Medicaid adult dental benefits, reimbursement rates, provider participation, scope-of-practice for hygienists, FQHC expansions, and (in 2020) pandemic-related shutdowns. The paper does not control for or even systematically document coincident policy changes by state and year.
4. **The outcome is broad.** “Visited dentist in past year” is a utilization measure combining supply and demand. Dental therapists primarily expand supply for basic restorative/preventive services—yet whether that increases *any visit* depends on insurance, prices, appointment availability, and consumer behavior. Without subgroup analysis (Medicaid/uninsured; rural; low-income) the null/negative average is not very informative.

### Placebos and robustness
- Only one robustness check is reported: alternative comparison group (p. 12–13; Appendix B p. 17).
- Missing at top-journal bar:
  - Leave-one-treated-state-out sensitivity (with 9 treated states this is essential).
  - Alternative outcomes (unmet need due to cost; teeth cleaning; ED dental visits).
  - Alternative estimators (Sun–Abraham; Borusyak–Jaravel–Spiess imputation; de Chaisemartin–D’Haultfoeuille) to show robustness to estimator choice.
  - Donut/excluding 2020, or explicitly modeling pandemic shock.
  - Randomization inference / permutation tests for staggered DiD with few treated units.

### Do conclusions follow from evidence?
- The current conclusion (“authorization is associated with a decrease”) is statistically supported in the narrow specification.
- But the paper sometimes drifts toward causal language while also conceding endogeneity. For a top journal you must be sharper: either (i) credibly identify a causal effect, or (ii) reframe explicitly as “reduced-form association with policy adoption” and pivot to political economy of adoption.

### Limitations
- Limitations are discussed (p. 13–14). This is good, but in a top journal, limitations that undermine identification must be *addressed*, not merely acknowledged.

---

# 4. LITERATURE (Missing references + BibTeX)

### Methods literature missing (high priority)
You cite Callaway–Sant’Anna and Goodman-Bacon (good). But you should also cite and engage:

1) **Sun & Abraham (2021)** event-study with heterogeneous treatment effects  
```bibtex
@article{SunAbraham2021,
  author = {Sun, Liyang and Abraham, Sarah},
  title = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {175--199}
}
```

2) **Borusyak, Jaravel & Spiess (2021)** imputation DiD  
```bibtex
@article{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year = {2021}
}
```
(If you prefer journal-published refs only, cite the working paper and/or subsequent publication if available by your submission date.)

3) **de Chaisemartin & D’Haultfoeuille (2020)** two-way FE pitfalls and robust DiD  
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author = {de Chaisemartin, Cl{\'e}ment and d'Haultfoeuille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

4) **Roth (2022)** pretrend testing / design sensitivity in event studies  
```bibtex
@article{Roth2022,
  author = {Roth, Jonathan},
  title = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year = {2022},
  volume = {4},
  number = {3},
  pages = {305--322}
}
```

5) **Conley & Taber (2011)** inference in DiD with few treated groups (very relevant here)  
```bibtex
@article{ConleyTaber2011,
  author = {Conley, Timothy G. and Taber, Christopher R.},
  title = {Inference with {D}ifference in {D}ifferences with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year = {2011},
  volume = {93},
  number = {1},
  pages = {113--125}
}
```

### Domain/policy literature missing (high priority)
You cite NASEM (2011) and a Minnesota report, but for top outlets you need peer-reviewed evidence on dental access and policy levers:

6) **Medicaid adult dental benefits and utilization** (there is a sizable literature; you should cite at least a couple credible empirical papers—NBER/Health Econ/JHE). One example often cited in oral health policy discussions:
```bibtex
@article{Choi2011MedicaidDental,
  author = {Choi, Mary K.},
  title = {The Impact of Medicaid Insurance Coverage on Dental Service Use},
  journal = {Journal of Health Economics},
  year = {2011},
  volume = {30},
  number = {5},
  pages = {1020--1031}
}
```
(If you use different canonical papers, fine—but you must engage this literature because changes in Medicaid dental benefits are major confounds.)

7) **Dental therapist empirical evaluations** beyond descriptive Minnesota reports (even if limited, cite what exists in journals; also cite systematic reviews on midlevel providers in dentistry). For example:
```bibtex
@article{WrightGrahamHayes2016,
  author = {Wright, J. Timothy and Graham, Frances and Hayes, Christopher},
  title = {A Systematic Review of the Effectiveness and Efficiency of Dental Therapists},
  journal = {Journal of the American Dental Association},
  year = {2016},
  volume = {147},
  number = {8},
  pages = {641--651}
}
```
(Please verify the exact bibliographic details you intend to use; the key point is you need systematic-review and peer-reviewed evaluation citations, not only agency reports.)

8) **Scope-of-practice and provider supply** (broader health workforce and SOP literature can help you interpret substitution vs expansion). A classic in physician assistants/nurse practitioners is:
```bibtex
@article{KleinerMarierParkWing2016,
  author = {Kleiner, Morris M. and Marier, Allison and Park, Kyoung Won and Wing, Coady},
  title = {Relaxing Occupational Licensing Requirements: Analyzing Wages and Prices for a Medical Service},
  journal = {Journal of Law and Economics},
  year = {2016},
  volume = {59},
  number = {2},
  pages = {261--291}
}
```
(Not dentistry-specific, but directly relevant to licensing/SOP and market outcomes.)

### Positioning / contribution
Right now the contribution is framed as “first quasi-experimental population-level evaluation with modern DiD” (p. 3). That could be publishable in a field journal *if* identification were stronger and the policy variation richer. For a top general-interest journal, you need either:
- a cleaner identification angle (policy quasi-randomness, or strong design-based evidence), or
- richer outcomes/mechanisms and a more general contribution to policy evaluation under endogenous adoption.

---

# 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Mostly acceptable, but the institutional and policy narrative is underdeveloped and sometimes reads like a policy brief.
- Move beyond bullets in Background and use that space to explain: what exactly changes legally, what supervision rules are, where therapists can practice, how Medicaid billing works, and how quickly each state implemented.

### (b) Narrative flow
- The intro (p. 2–3) motivates the question and states the result early (good).
- But the “hook” is generic and the payoff is not sharpened: why does a **−1.3 pp** reduced-form change matter, and what does it teach economists beyond “policy adoption is endogenous”?

### (c) Sentence quality
- Clear and professional, but not yet “top journal” crisp. Too many claims are unaccompanied by concrete institutional detail or quantitative context (e.g., how many dental therapists exist in these states by 2020?).

### (d) Accessibility
- Econometrics choices are explained at a high level (CS vs TWFE) (p. 8–9), which is good.
- But the key conceptual issue—authorization vs implementation—is not confronted head-on in the research design.

### (e) Figures/Tables quality
- Figures 1–2 are serviceable; Figure 3 needs a complete redesign.
- Tables are clear but incomplete for transparency (need event-study coefficient table; cohort-specific estimates; weights).

---

# 6. CONSTRUCTIVE SUGGESTIONS (What would make this publishable)

## A. Redesign treatment: measure *implementation intensity*, not just authorization
At minimum, assemble state-year measures of:
- number of licensed dental therapists,
- number actively practicing,
- claims volume (Medicaid) involving dental therapists,
- training program openings / graduates,
- supervision restrictions and site restrictions,
- Medicaid reimbursement policies for therapist-delivered services.

Then estimate dose–response/event studies using intensity (or an IV where authorization shifts intensity, though IV validity is nontrivial).

## B. Expand outcomes (to match policy mechanisms)
“Any dental visit” is very broad. Add:
- preventive visit / cleaning (if available),
- unmet dental need due to cost,
- tooth loss / self-reported oral health (if available),
- ED visits for non-traumatic dental conditions (HCUP state ED data) to capture access failures,
- utilization for low-income/rural populations (heterogeneity).

## C. Address 2020 explicitly
Given COVID, you should:
- run specifications excluding 2020,
- include a COVID shock control interacted with stringency measures (or at least region-by-year shocks),
- show whether results are driven by the 2018 and 2020 cohorts loading on the pandemic period.

## D. Strengthen inference with few treated units
With 9 treated states:
- implement **randomization inference / permutation tests** (placebo assignment of adoption years),
- use **Conley–Taber** style inference or small-sample corrections,
- provide leave-one-out influence diagnostics.

## E. Cohort-specific and state-specific results
Right now, the paper risks being “one negative ATT.” Show:
- cohort-specific ATTs (ME vs VT vs 2018 vs 2020 cohorts),
- state-level event studies (even if noisy),
- whether a small number of states drive the sign.

## F. Political economy of adoption (if you lean into endogeneity)
If the main story is “adoption responds to declining access,” then make that the paper:
- estimate an adoption hazard model: are declines in visits, dentist supply, Medicaid participation, rural HPSAs predictive of adoption?
- show anticipatory declines relative to non-adopters (beyond one pre-coefficient).
This could turn a weakness into a contribution—*but only if executed seriously*.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Policy question is important and timely.
- Correctly avoids naïve TWFE; uses **Callaway–Sant’Anna**.
- Transparent about limitations and the possibility of reverse causation.

### Critical weaknesses
- **Identification is not credible at top-journal standard**: authorization is a weak proxy for treatment; adoption is endogenous; only 5 time periods; pre-trends test is uninformative.
- **Outcome choice** is too broad and not mechanism-aligned.
- **Inference and robustness are incomplete** given few treated units and a pandemic period.
- **Paper is far too short** and under-cited for a top general-interest outlet; it lacks the depth, robustness, and institutional detail required.

### Specific improvements that are necessary (not optional)
1. Implementation/intensity measures and mechanism-linked outcomes.
2. Robustness to excluding 2020 and other confounds (Medicaid dental policy changes).
3. Small-treated-units inference (RI/permutation; Conley–Taber).
4. Cohort/state heterogeneity and influence diagnostics.
5. Major literature expansion and a rewritten institutional background.

---

DECISION: REJECT AND RESUBMIT